X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-expansion-of-imbruvica-ibrutinib-label-in-the-u-s-to-include-oral-suspension-formulation-for-adult-patients-in-its-approved-indications
https://www.fiercepharma.com/pharma/ash-after-pulling-approvals-april-abbvie-plots-imbruvica-comeback-mantle-cell-lymphoma
https://www.globenewswire.com//news-release/2023/12/11/2793570/0/en/New-Data-Presented-at-ASH-from-the-Phase-3-GLOW-Study-Show-Fixed-Duration-First-Line-Treatment-with-IMBRUVICA-ibrutinib-Plus-Venetoclax-Demonstrated-an-Overall-Survival-Rate-of-Mor.html
https://www.fiercepharma.com/pharma/abbvies-imbruvica-brukinsa-patent-suit-may-have-merit-and-beigene-will-likely-settle-expert
https://www.onclive.com/view/ibrutinib-plus-chemoimmunotherapy-fails-to-improve-pfs-in-pretreated-follicular-lymphoma-mzl
https://www.onclive.com/view/ibrutinib-obinutuzumab-venetoclax-triplet-elicits-sustained-clinical-benefit-in-mantle-cell-lymphoma
https://www.fiercepharma.com/pharma/beigenes-brukinsa-surging-cll-abbvie-gets-win-uk-imbruvica-venclyxta-combo
https://www.pharmiweb.com/press-release/2023-04-21/nice-gives-green-light-to-ibrutinib-plus-venetoclax-as-first-line-treatment-option-for-chronic-lymphocytic-leukaemia
https://news.abbvie.com/news/press-releases/update-on-imbruvica-ibrutinib-us-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications.htm
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-pfizer-abbvie-drugs-likely-face-us-price-negotiation-2023-03-13/
https://www.businesswire.com/news/home/20221213005484/en/%C2%A0BeiGene%E2%80%99s-BRUKINSA%C2%AE-zanubrutinib-Demonstrated-Superior-Progression-Free-Survival-Over-IMBRUVICA%C2%AE-ibrutinib-in-Chronic-Lymphocytic-Leukemia-in-Late-Breaker-at-ASH
https://www.prnewswire.com/news-releases/real-world-study-shows-patients-treated-with-imbruvica-ibrutinib-were-less-likely-to-initiate-a-next-line-treatment-than-patients-on-acalabrutinib-in-first-line-chronic-lymphocytic-leukemia-301700506.html
https://www.prnewswire.com/news-releases/abbvie-presents-data-at-the-64th-american-society-of-hematology-ash-annual-meeting-adds-to-robust-imbruvica-ibrutinib-science-301699749.html
https://www.prnewswire.com/news-releases/new-results-from-the-phase-3-glow-study-of-fixed-duration-treatment-with-imbruvica-ibrutinib-plus-venetoclax-demonstrate-robust-efficacy-and-sustained-response-in-older-unfit-patients-with-previously-untreated-chronic-lymphocy-301699746.html
https://www.globenewswire.com/news-release/2022/12/10/2571411/0/en/Oncternal-Therapeutics-Presents-Updated-Interim-Data-for-Zilovertamab-in-Combination-with-Ibrutinib-at-ASH-2022.html
https://www.fiercepharma.com/pharma/abbvie-jjs-imbruvica-under-serious-threat-beigenes-brukinsa-delivers-all-around-head-head
https://ir.beigene.com/news/beigene-to-present-final-pfs-results-from-alpine-trial-demonstrating-superior-pfs-for-brukinsa-versus-imbruvica-in/3eaa7080-547b-4792-a670-a496e02046f4/
https://www.fiercepharma.com/pharma/beigene-heaps-more-pressure-abbvie-and-jj-new-brukinsa-imbruvica-head-head-win
https://endpts.com/ema-makes-new-recommendations-for-imbruvica-medicines-with-terlipressin-over-respiratory-and-cardiovascular-risks/
https://www.biospace.com/article/releases/u-s-fda-approves-imbruvica-ibrutinib-as-first-and-only-btki-treatment-for-pediatric-patients-with-chronic-graft-versus-host-disease/
https://news.abbvie.com/news/press-releases/children-with-chronic-graft-versus-host-disease-cgvhd-may-now-be-prescribed-imbruvica-ibrutinib.htm
https://www.fiercepharma.com/financials/abbvie-soars-thanks-immunology-profile-humira-skyrizi-and-rinvoq
https://www.fiercebiotech.com/biotech/abbvie-pens-imbruvica-supply-pact-support-pivotal-oncternal-trial
https://www.fiercepharma.com/pharma/planning-all-oral-once-daily-regimen-jj-gets-ema-backing-imbruvica-venetoclax-combination
https://www.prnewswire.com/news-releases/new-imbruvica-ibrutinib-data-in-fixed-duration-combination-regimen-presented-at-eha-2022-shows-deep-durable-response-at-three-years-in-untreated-chronic-lymphocytic-leukemia-301565696.html
https://www.globenewswire.com/news-release/2022/06/10/2460530/0/en/Oncternal-Therapeutics-Presents-Rationale-and-Plans-for-its-Registrational-Phase-3-Study-Evaluating-Zilovertamab-in-Combination-with-Ibrutinib-at-the-EHA-2022-Congress.html
https://www.reuters.com/business/healthcare-pharmaceuticals/jj-abbvie-cancer-drug-significantly-slows-progression-rare-lymphoma-study-2022-06-03/
https://www.globenewswire.com/news-release/2022/05/26/2451680/0/en/Oncternal-Therapeutics-Presents-Updated-Interim-Data-for-Zilovertamab-in-Combination-with-Ibrutinib-at-ASCO-2022.html
https://www.prnewswire.com/news-releases/abbvie-seeks-new-indication-for-imbruvica-ibrutinib-in-pediatric-patients-with-chronic-graft-versus-host-disease-cgvhd-301491494.html
https://www.reuters.com/business/healthcare-pharmaceuticals/jj-sees-potential-14-new-multibillion-dollar-drugs-by-2025-2021-11-18/
https://www.pharmaceutical-technology.com/news/jj-split-consumer-health-pharmaceutical/
https://www.fiercepharma.com/marketing/michael-landon-s-daughter-urges-genetic-testing-for-pancreatic-cancer-risk-psa
https://www.nih.gov/news-events/news-releases/ibrutinib-improves-survival-younger-people-diffuse-large-b-cell-lymphoma
https://www.fiercebiotech.com/biotech/j-j-science-chief-stoffels-to-retire-after-decade-at-top-adding-to-c-suite-changes
https://www.fiercepharma.com/pharma/beigene-s-brukinsa-turns-up-heat-against-imbruvica-latest-lymphoma-nod
https://www.fiercepharma.com/pharma/don-t-underestimate-impact-abbvie-s-recent-patent-protection-win-analyst
https://www.morningstar.com/news/dow-jones/202108197874/abbvie-says-court-rules-imbruvica-patents-valid-in-generic-challenge
https://www.indiainfoline.com/article/news-sector-pharma-healthcare/natco-pharma-stock-dips-over-4-after-us-district-court-verdict-on-patent-litigation-121082000298_1.html
https://www.cancertherapyadvisor.com/home/news/conference-coverage/eha2021-virtual-congress/chronic-leukemia-cll-ibrutinib-venetoclax-therapy-improve-outcome/
https://www.businesswire.com/news/home/20210611005105/en/BeiGene-Presents-ALPINE-Results-at-EHA2021-Demonstrating-Both-Efficacy-and-Safety-Advantages-of-BRUKINSA%C2%AE-Zanubrutinib-in-Head-to-Head-Comparison-to-Ibrutinib-in-Chronic-Lymphocytic-Leukemia/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT
http://www.pharmatimes.com/news/imbruvicavenclyxto_tops_gazyva_plus_chemo_in_first-line_cllsll_1371653
https://news.abbvie.com/news/press-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study.htm
https://www.prnewswire.com/news-releases/new-phase-3-study-results-show-imbruvica-ibrutinib-based-combination-regimen-as-an-all-oral-fixed-duration-treatment-demonstrated-superior-progression-free-survival-in-adult-patients-with-previously-untreated-chronic-lymphocyti-301311195.html
https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study-301311176.html
http://www.pharmatimes.com/news/imbruvicavenclyxto_tops_gazyva_plus_chemo_in_first-line_cllsll_1371653
https://www.fiercepharma.com/pharma/a-shorter-leukemia-therapy-abbvie-j-j-tee-up-fda-filing-for-imbruvica-venclexta-fixed
https://www.fiercepharma.com/pharma/a-shorter-leukemia-therapy-abbvie-j-j-tee-up-fda-filing-for-imbruvica-venclexta-fixed
https://www.prnewswire.com/news-releases/european-hematology-association--first-line-ibrutinib--venetoclax-is-superior-to-chlorambucil--obinutuzumab-for-chronic-lymphocytic-leukemiasmall-lymphocyte-lymphoma-301310009.html
Market Place
Share 
